...
首页> 外文期刊>Chinese Medical Journal >Effects of leukotriene receptor antagonist on chronic obstractive pulmonary disease induced pulmonary hypertension
【24h】

Effects of leukotriene receptor antagonist on chronic obstractive pulmonary disease induced pulmonary hypertension

机译:白三烯受体拮抗剂对慢性阻塞性肺疾病致肺动脉高压的作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objectives To assess the hemodynamic, oxygen-dynamic and ventilative effects of Zafirlukast in chronic obstructive pulmonary disease (COPD) induced chronic cor pulmonale at acute exacerbation stage and the mechanisms of Zafirlukast efficacy. Methods Eleven cases of chronic cor pulmonale at acute exacerbation were examinted using Swan-Ganz catheter and peripheral intra-artery catheter. The hemodynamic, oxygen-dynamic parameters and respiratory rate, plasma endothelium-1 (ET-1) level, and urea leukotriene E_4(LTE_4) level were measured before and at the 1st, 3rd, 5th, 7th, 9th, 12th hour after taking 40 mg Zafirlukast orally. Artarial and mixed venous blood gas analyses were done correspondingly. Results The average pulmonary arterial pressure (mPAP) and pulmonary vascular resistance index (PVRI) were lowered at the 3rd hour after taking Zafirlukast by 23% and 36.5%, respectively. They returned to the baseline around 12th hour. Respiratory rate decreased significantly within the 3rd-7th hour after taking Zafirlukast. LTE_4 and ET-1 levels lowered at the 3rd hour and showed a positive correlation with change of mPAP. Conclusions Zafirlukast can reduce mPAP, pulmonary vascular resistance (PVR) and does not affect the ambulatory blood pressure monitoring (ABPM) and oxygenation in cases of chronic cor pulmonale at acute exacerbation stage. Zafirlukast may play a role as an alternative to decrease PAP in COPD patients.
机译:目的评估Zafirlukast在慢性阻塞性肺疾病(COPD)诱发的急性肺急性加重期的血流动力学,氧气动力学和通气作用以及Zafirlukast疗效的机制。方法采用Swan-Ganz导管和外周动脉内导管检查11例慢性加重期慢性肺炎患者。在服药后第1、3、5、7、9、12小时之前和之后分别测量血流动力学,氧动力学参数和呼吸频率,血浆内皮-1(ET-1)水平和尿素白三烯E_4(LTE_4)水平。 40 mg Zafirlukast口服。分别进行了动脉和混合静脉血气分析。结果服用扎鲁司特后第3小时,平均肺动脉压(mPAP)和肺血管阻力指数(PVRI)分别降低了23%和36.5%。他们在第12小时左右回到基线。服用扎鲁司特后第3-7个小时内呼吸频率显着下降。 LTE_4和ET-1水平在第3小时降低,并且与mPAP的变化呈正相关。结论扎鲁司特可以减轻急性加重期肺动脉高压患者的mPAP,肺血管阻力(PVR),并且不影响动态血压监测(ABPM)和氧合。扎鲁司特可以作为降低COPD患者PAP的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号